Cancer represents a key challenge in medical science, manifesting as a disease where the immune system fails to recognize and eliminate tumor cells. The phenomenon of immune evasion by cancer cells ...
Characterization of TP53 mutations in actionable driver-negative non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...
A study led by the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong ...
QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...
When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
New data show hip osteoarthritis does not raise the risk of immune checkpoint inhibitor–induced inflammatory arthritis, while ...
In 2011, the first in a new generation of anticancer drugs called checkpoint inhibitors was approved. The drug, known as ipilimumab or Yervoy, stood apart from standard cancer treatments. It worked by ...
News-Medical.Net on MSN
Bacterial metabolite enhances immune checkpoint therapy against lung cancer
UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback